Compare CVS Health Corp (CVS) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Nucor Corporation — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while Nucor Corporation trades at $248 (market cap $55.91B). The key difference: CVS Health Corp is far larger — about 2× Nucor Corporation's market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Nucor Corporation for 78 Days on average.
| CVS | NUE | |
|---|---|---|
Market Cap | $112.49B | $55.91B |
Volume | 8,467,392 | 1,062,743 |
Sector | Health | Basic Materials |
52-Week High | $110.60 | $274.74 |
52-Week Low | $70.08 | $131.78 |
Typical Hold Time | 83 Days | 78 Days |
Enterprise Value | $174.83B | $60.32B |
Dividend Yield | 3.02% | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Nucor (NUE) trades at $246.14, down 1.96% on the day, amid a neutral technical signal with mixed moving averages and oscillators. Recent earnings show Q1 and Q2 2026 beats, but Q3 guidance of $5.75 EPS is pending. Revenue for 2025 was $32.49B with a net income margin of 7.99%, while 2026 projections indicate a rebound to $36.1B revenue and 7.98% margin. The company maintains a strong balance sheet with $4.14B cash and a debt-to-asset ratio of 20.23% for 2025.
Outlook remains cautiously optimistic with a consensus price target of $266.88, implying ~8% upside, supported by 57.58% analyst buy ratings. Risks include competitive pressures from a new $15B Iowa steel mill and volatile steel prices, but Nucor's low-cost operations and dividend consistency (214th consecutive payout) provide stability. Investors should monitor Q3 earnings for confirmation of growth trajectory amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
